Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-18. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Securing national PBM reimbursement for oral GLP-1 therapy Foundayo increases volume access and long-term pharmaceutical franchise cash flows for LLY.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factEli Lilly generated $27.7 billion in first-half 2026 sales from its GLP-1 franchise, led by Mounjaro and Zepbound. |
| What else was confirmed? | Reported factOral obesity candidate Foundayo secured formulary coverage across major pharmacy benefit managers (PBMs). |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownWeekly IQVIA prescription volume trends for Mounjaro, Zepbound, and Foundayo — Weekly TRx and NRx data confirming ongoing market share capture versus Wegovy. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Eli Lilly generated $27.7 billion in first-half 2026 sales from its GLP-1 franchise, led by Mounjaro and Zepbound.
- · Oral obesity candidate Foundayo secured formulary coverage across major pharmacy benefit managers (PBMs).
- · Non-incretin newer therapies grew 121% in Q2 2026, contributing to therapeutic diversification.
- · LLY shares declined approximately 7% over the past month amid broader market consolidation.
Public research record
Research framework · page evidenceCompleted event assessment
prescription volume growth and commercial formulary tier access
| Type | Claim | Scope |
|---|---|---|
| Assumption | Eli Lilly generated $27.7 billion in first-half 2026 sales from its GLP-1 franchise, led by Mounjaro and Zepbound. | 2026-09-18 |
| Interpretation | prescription volume growth and commercial formulary tier access | LLY |
Countercase, invalidators, and sources
Rapid commercial dispensing of Foundayo accelerates full-year metabolic revenue beyond $60 billion.
- · Weekly IQVIA prescription volume trends for Mounjaro, Zepbound, and Foundayo — Weekly TRx and NRx data confirming ongoing market share capture versus Wegovy.
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? · 2026-09-17
What remains unresolved
- Base path
- LLY maintains leading market share in obesity care with consistent double-digit revenue expansion.
- Adverse path
- PBM price concessions and compounding competition erode net realized price per dose.
- Supportive path
- Rapid commercial dispensing of Foundayo accelerates full-year metabolic revenue beyond $60 billion.
- · Weekly IQVIA prescription volume trends for Mounjaro, Zepbound, and Foundayo — Weekly TRx and NRx data confirming ongoing market share capture versus Wegovy.this week
Evidence
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?2026-09-17
“Eli Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, generated $27.7 billion in first-half 2026 sales... oral obesity pill Foundayo shows encouraging uptake with coverage across major PBMs”
Supports: Eli Lilly GLP-1 sales reached $27.7B in 1H 2026 as oral pill Foundayo secured major PBM coverage.